The Food and Drug Administration approved Fayuvi on September 17, the first therapy cleared to treat the underlying cause of Sanfilippo syndrome type A. Here is what the approval package actually shows — including the parts that warrant caution. For families whose children have mucopolysaccharidosis type IIIA (MPS IIIA), better known as Sanfilippo syndrome type A, there has never been…

Wellness

discover practical tips and motivation to start living a healthier lifestyle. embrace wellness with easy habits, inspiration, and guidance to begin your journey to better health today.

Women's

Diet and Weight Loss

Patient Stories

Senior